** Shares of rare neurological disease-focused pharma company Harmony Biosciences HRMY.O up 3.7% at $35.44 premarket

** Company posts Q4 adj profit of $1.08 per share, beating analysts' estimates of 74 cents per share, according to data compiled by LSEG

** Co records Q4 sales of sleep disorder drug, Wakix, at $201.3 million, beating analysts' estimates of $200 million

** Expects 2025 net product revenue of $820 million to $860 million, midpoint of which is below analysts' estimates of $848 million

** In the last 12 months, HRMY rose 4.7%

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))